login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

ESC sets consensus over TAVI


Friday, 02 Sep 2011 12:33

by Dario Remigi


The annual meeting of the European Society of Cardiology, in Paris, has enhanced the status of TAVI as the “gold standard” for inoperable patients suffering from severe aortic stenosis. However, concerns about high rates of permanent pacemaker implantation after TAVI remain, specialists say. 


TAVI was introduced nearly 10 years ago as an alternative procedure with limited application but it has expanded significantly in the course of recent years. Despite its increasing popularity among physicians, however, haemodynamic performance and valve durability remain unknown.


Now, for the first time, data from 393 consecutive patients undergoing implantation of a CoreValve self-expandable prosthesis at the German Heart Centre in Munich, Germany, have been presented: they show a “sustained improvement of haemodynamic values” and no signs of early or “unexpected” deterioration of the valve at three-year of follow-up.

 

“We all know that any biological valve gets deteriorated after a certain period of time, would this be 10 or 12 years. We know exactly when this will occur to a traditional heart valve, but we do not know when this will occur to a transcatheter valve. Now we know that after three years the haemodynamic performance of transcatheter valves is unchanged,” Anke Optiz, co-investigator of the study, told Cardiovascular News

 

Based on the societies guidelines, so far most of the TAVI registries have included patients with high logistic Euroscore (20% or higher). However data presented at ESC this year suggest that 100% procedural success is possible even in a patient population with lower logistic Euroscore. The prospective, single-centre data refer to a cohort of 177 patients who underwent implantation with the Edwards valve at the Rouen University Hospital, France, between May 2006 and January 2011.

 

“We examined the population with lower logistic Euroscore because we were under the impression that these patients reacted better to TAVI as they were younger and had fewer comorbidities,” said Matthieu Godin, co-investigator of the study. “The retrospective analysis showed absence of death at 30 days for this specific group of low-risk patients. This result was beyond our expectations,” he added. Despite this data, Godin noted, “we should never forget that conventional surgery remains the gold standard for the lower-risk patient population”. 

 

The Rouen experience is not isolated. An increasing trend to include lower risk patients into TAVI registries has been observed across European countries in the last few years. But according to both cardiology and cardiac surgery specialists discussing TAVI at ESC, this should not become standard practice.

 

“We can say that TAVI is doing relatively well – better than conventional surgery – within a certain high-risk group. But it is difficult to say that TAVI will necessarily do better in the lower group as well, because we do not have evidence of better results with TAVI compared to conventional surgery in any trial, including the US PARTNER trial where TAVI results are extremely good,” Olaf Wendler, clinical director, Cardiothoracic Surgery, King’s College Hospital, London, UK, told Cardiovascular News. “That is why I think TAVI should focus on patients who would clearly benefit from this new treatment immediately.”  

 




Add New Comment

Related Items


Most popular


No severe paravalvular leak with Acurate Neo TF
Monday, 29 Sep 2014
Data presented at PCR London Valves (28–30 September, London, UK) indicate that the Acurate Neo transfemoral TAVI system, which recently received the CE mark, is not associated with any incidences of ... No severe paravalvular leak with Acurate Neo TF

ABSORB II study shows Absorb is comparable to Xience drug-eluting stent
Wednesday, 17 Sep 2014
At one year, overall clinical outcomes for Absorb (Abbott) were comparable to Xience (Abbott), and people treated with Absorb experienced a significantly lower rate of angina. ABSORB II study shows Absorb is comparable to Xience drug-eluting stent

First-in-man percutaneous repair of tricuspid valve performed
Wednesday, 08 Oct 2014
Mitralign has reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation. The company also announced that Joachim Schofer and Rebecca H... First-in-man percutaneous repair of tricuspid valve performed

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Profiles


Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions